Small Molecule API Market is projected to reach a total of US$ 290.76 Billion by 2032 at a CAGR of 5%

A recently published study by FMI expects the global demand for Small Molecule API Market to increase at a CAGR of 5% during the forecast period between 2022 and 2032, reaching a total of US$ 290.76 Billion by 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 4.5%.

In-House and outsourcing manufacturing of small molecule API continue to be hot topics in the pharmaceutical sector. The demand for outsource manufacturing in the small molecule market has been on the rise because of increasing production cost and burden management. Subsequently, rising incidence of chronic diseases, besides investment in research and development (R&D) initiatives have been enabling growth.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4591

Over the years, increased use of novel technologies and the emergence of specialty medicines have been leading to a paradigm shift in the industry. Furthermore, smaller volumes of production are projected to witness a surge. The increasing production of the number of products being launched are a result of flexible manufacturing units and robust processes developed to meet the demand.

Key Takeaways from the Market Study

  • China is expected to register 5.5% CAGR during the forecast period
  • Japan to emerge as another important market for small molecule API, registering a CAGR of 5.4%
  • Germany is projected to account for approximately 30% of the global market share.
  • Standard APIs will continue to hold a maximum share of 79.6% in 2022
  • Oncology accounts for 26.6% of the Small Molecule API Market share by therapeutic area.

“API manufacturing has proven to be quite effective in the last few years. Besides this, factors such as increasing incidence of cancer and subsequently rising demand for effective diagnosis and R&D in oncology therapeutic will fuel the demand for small molecule oncology therapy.” says an analyst at FMI. 

Talk to Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-4591

Market Competition

Key players in the Small Molecule API market are Pfizer Inc., Johnson Matthey, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., Sanofi S.A., Novartis AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, GILEAD Science Inc., Albany Molecular Research Inc., AstraZeneca, Merck & Co, Inc., BASF SE, Teva Pharmaceuticals, and Hoffmann-La Roche Ltd.

  • In March 2021, U.S. Food and Drug Administration (FDA) has accepted New Drug Application for gefapixant, an orally administered for the Molecule Type of refractory chronic cough (RCC) in adults.
  • In March 2022, Sumitomo Chemical Co., Ltd. announced its investment to build a new manufacturing facility in Japan to meet the surge in demand for high-quality small molecule APIs and intermediates.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global small molecule API market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Molecule Type (Standard API, HPAPI), Production (Captive/In-House, Out Source), Application (Clinical, Commercial), Therapeutic Area & Region across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa).

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-4591

Key Segments Profiled in the Small Molecule API Market Industry Survey

By Molecule Type:

  • Standard API
  • HPAPI

By Production:

  • Captive/In-House
  • Outsourced

By Application:

  • Clinical
  • Commercial

By Therapeutic Area:

  • Cardiovascular Diseases
  • Respiratory Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Oncology
  • Immunology
  • Neurology
  • Urology
  • Dermatology
  • Ophthalmology
  • General Health
  • Others

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these